Tactic Pharma Llc Sells 33,334 Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) Stock

Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) major shareholder Tactic Pharma Llc sold 33,334 shares of the firm's stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $35.00, for a total value of $1,166,690.00. Following the sale, the insider now directly owns 822,255 shares of the company's stock, valued at $28,778,925. This represents a 3.90 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.

Monopar Therapeutics Stock Down 4.6 %

Shares of NASDAQ:MNPR traded down $1.34 during trading on Wednesday, reaching $27.58. 5,491 shares of the company traded hands, compared to its average volume of 49,131. The firm has a market capitalization of $168.57 million, a PE ratio of -14.00 and a beta of 1.01. Monopar Therapeutics Inc. has a 52 week low of $1.72 and a 52 week high of $54.30. The company's 50 day moving average is $37.74 and its two-hundred day moving average is $25.54.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last posted its quarterly earnings data on Monday, March 31st. The company reported ($2.23) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($1.87). As a group, research analysts anticipate that Monopar Therapeutics Inc. will post -1.65 EPS for the current year.

Remove Ads

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Janus Henderson Group PLC bought a new position in shares of Monopar Therapeutics in the 4th quarter valued at $23,435,000. Adage Capital Partners GP L.L.C. bought a new position in shares of Monopar Therapeutics during the fourth quarter valued at $13,182,000. RA Capital Management L.P. acquired a new position in Monopar Therapeutics during the 4th quarter worth about $11,247,000. Point72 Asset Management L.P. acquired a new position in shares of Monopar Therapeutics in the fourth quarter worth approximately $3,694,000. Finally, ADAR1 Capital Management LLC bought a new stake in shares of Monopar Therapeutics in the 4th quarter valued at $2,861,000. 1.83% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. Piper Sandler restated an "overweight" rating and set a $76.00 price objective on shares of Monopar Therapeutics in a report on Wednesday, March 19th. Jones Trading restated a "hold" rating on shares of Monopar Therapeutics in a research note on Wednesday, April 2nd. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $40.00 price objective on shares of Monopar Therapeutics in a report on Tuesday, April 1st. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $44.00.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.